Summary.-Adriamycin and cyclophosphamide are active agents in human and experimental tumours. Using the L1210 murine leukaemia, their effectiveness alone and in combination was studied. The combination is highly synergistic in this tumour, resulting in a greater than 5000 survival rate when the agents used alone at optimal doses are not curative. DNA synthesis by tumour cells is substantially inhibited and the total ascitic population much reduced. In contrast, DNA synthesis in sensitive host tissues is less disturbed. There is no major difference in the pharmacology of the agents whether given alone or in combination. In very advanced disease the combination is no better than treatment with cyclophosphamide alone. The combination of adriamycin and melphalan in L1210 leukaemia also produces superior results to those obtained using either drug alone at its optimal dosage. CYCLOPHOSPHAMIDE (CTX), an alkylating agent with activity against a wide range ofexperimental and human tumours, has pronounced effects against the L1210 transplantable leukaemia, even in relatively advanced disease (Lane, 1959) . L-phenylalanine mustard (Melphalan, L-PAM) is also active in L1210, although this agent has been less thoroughly studied than CTX (Goldin and Carter 1973) . More recently, the anthracyclene drugs have been shown to have definite but limited activity against this tumour (Hoshino et al., 1972) . Of the anthracyclenes, adriamycin (ADR) is clearly superior to daunorubicin in L1 210 and most other experimental tumours (Sandberg et al., 1970; Di Marco and Lenaz, 1973) and in most human malignancies (Bonadonna et al., 1970) .
Recent reports on the use of the combination of CTX and ADR have been encouraging, both in human studies (Salmon and Jones, 1974; Muggia et al., 1974; Jones, Durie and Salmon, 1975; Parker et al., 1975) , and in several animal systems (Wodinsky, Swiniarski and Venditti, 1974; Corbett et al., 1975) .
The purpose of this study was to further evaluate this combination in L1210 leukaemia with respect to (1) the extent of disease, (2) inhibition of normal and leukaemic cell DNA synthesis by the combination, and (3) to investigate the alkylating agent employed. For the experiments designed to investigate DNA synthesis during treatment, a tritiated thymidine labelling technique was used. Groups of 3 &nimals were killed by cervical dislocation at various timegfollowing treatment. Thirty minutes before killing, tritiated thymidine (specific activity 6-9 Ci/ mmol, New England Nuclear, Boston, Mass.) was injected intraperitoneally in a volume of 0 5 ml (total dose 50 4uCi/animal). Ascites, small intestine and both femora were removed and DNA extractions were made from these tissues following the method of Burton (1956) . The amount of DNA in each sample was read colourimetrically and an aliquot was also added to Aquasol scintillation fluid (New England Nuclear, Boston, Mass.) and read in a Beckman Scintillation counter for 5 min. Results were expressed as disintigrations/min/g of DNA.
Total ascitic cell count was performed in order to confirm that inhibition of DNA synthesis did in fact lead to cell kill, and also to follow the progress of tumour growth during treatment either with a single agent or the combination. The pbpulations of tumour cells were studied Wsing the cytofluorograph and these results will be reported separately.
In order to investigate the tissue distribution of CTX or ADR when given singly or together, a series of experiments was performed in which tissues were extracted at various times following treatment with either a single agent or both drugs in combination.
Groups of animals were treated with ADR 10 mg/kg, CTX 100 mg/kg, or a combination of these drugs at the same dosage given by simultaneous intraperitoneal injection. Groups of 3 animals were killed at various times following treatment and the livers and ascitic fluid removed. Ascitic fluid was centrifuged at 4°C and the supernatant retained for analysis. The livers were frozen immediately and maintained in liquid nitrogen until analysis. The tissues were extracted for ADR following the method of Yesair et al. (1972) and alkylating activity was measured according to the method of Friedman and Boger (1961) , in order to determine the level of cyclophosphamide activity. In all cases appropriate tissue blanks were run.
RESULTS

Treatment of L1 210 Leukaemia with ADR and CTX
The anti-tumour effects of ADR and CTX alone and in combination are shown in Table I , in which the results of 4 separate experiments have been pooled. Long survival was achieved only when the 2 agents were used in combination. Total ascitic cell counts following treatment All agents were capable of reducing the total number of ascitic cells (Fig. 2) . From the latter part of the curve, and especially from the data point at 72 h from treatment, it appears that the com- lents in the liver and ascitic fluid following treatment either with the single agents or the agents in combination. There is no major difference either in the curves for alkylating activity or the curves for total adriamycin fluorescence, irrespective of whether the agent was given alone or in combination with the other drug.
Adriamycin/melphalan treatment of L1210 addition of adriamycin led to a survival of greater than 50% in 2 groups.
DISCUSSION
The considerable effectiveness of CTX in L1210 leukaemia has been recognized for many years and studied extensively (Skipper, Schabel and Wilcox, 1964) . Other alkylating agents, including L-PAM, are also active in this experimental tumour (Goldin and Carter, 1973) . ADR, the most promising of the anthracyclene drugs, has been disappointing in this tumour despite its very wide spectrum of activity in other experimental tumours and in a number of human malignancies (Southern Research Institute, unpublished data; Blum and Carter, 1974) ADR has been shown to be a useful drug in combination with CTX for a number of tumours (Corbett et al., 1975 ) not including L1210, and the combination has been investigated in a Phase I study as well as in two further disease-specific studies (Muggia et al., 1974; Salmon and Jones, 1974; Parker et al; (v) The increased survival in the groups treated by combination therapy is explicable on the basis of almost complete inhibition of DNA synthesis. Both depth and duration of the inhibition of DNA synthesis is far greater for the tumour than the host cell. Reduction in the total ascitic cell population is more rapid and more completein the combination treated animals. The effectiveness of the ADR/CTX combination is not due to any change in the general pharmacological distribution of either agent. No major pharmacological differences were seen, irrespective of whether the agents were administered singly or together. (vi) The combination of ADR and L-PAM in L1210 produces wperior results to those obtained using either drug alone at optimal dosage. This suggests that the ADR/CTX synergy is not specific and that use of another alklating agent instead of CTX might also lead to encouraging results in the clinic. In view of the lesser gastrointestinal and genitourinary toxicity of L-PAM by comparison with CTX, this combination ought to be better tolerated in man. Both ADR and L-PAM are active agents in carcinomata of the breast (Ahmann et al., 1974; Fisher et al., 1975) and ovary (Smith and Rutledge, 1970; de Palo et al., 1974) 
